Evidence map›Paper›PMID 33354667›Full record

ArticleNeuro-oncology advances

Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults.

Jessica D Schulte, Robin A Buerki, Sarah Lapointe, Annette M Molinaro, Yalan Zhang, Javier E Villanueva-Meyer, Arie Perry, Joanna J Phillips, Tarik Tihan, Andrew W Bollen and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 3 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 3 syntheses or guidelines pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Jessica D SchulteDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-7135-9200
Robin A BuerkiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Sarah LapointeDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Annette M MolinaroDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Yalan ZhangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Javier E Villanueva-MeyerDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.
Arie PerryDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Joanna J PhillipsDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Tarik TihanDepartment of Pathology, University of California, San Francisco, San Francisco, California, USA.
Andrew W BollenDepartment of Pathology, University of California, San Francisco, San Francisco, California, USA.
Melike PekmezciDepartment of Pathology, University of California, San Francisco, San Francisco, California, USA.
Nicholas ButowskiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Nancy Ann Oberheim BushDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Jennie W TaylorDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Susan M ChangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Philip TheodosopoulosDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Manish K AghiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Shawn L Hervey-JumperDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0003-4699-260X
Mitchel S BergerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0003-1983-4892
David A SolomonDepartment of Pathology, University of California, San Francisco, San Francisco, California, USA.
Jennifer L ClarkeDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco · US

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Susan M Chang · 2002 to 2026
$57.4M
Tumor cell and microenvironment changes causing antiangiogenic therapy resistanceR01NS079697 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2013 to 2021
$3.2M
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systemsR01CA227136 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2018 to 2022
$2.2M
Cohesin gene mutations in tumorigenesisDP5OD021403 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SOLOMON, DAVID A. · 2015 to 2019
$2.0M
NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA227136NIH HHS DP5 OD021403NINDS NIH HHS R01 NS079697
6 · The paper itself

Abstract

background"Diffuse midline glioma (DMG), H3 K27M-mutant" is a new tumor entity established in the 2016 WHO classification of Tumors of the Central Nervous System that comprises a set of diffuse gliomas arising in midline structures and is molecularly defined by a K27M mutation in genes encoding the histone 3 variants H3.3 or H3.1. While this tumor entity is associated with poor prognosis in children, clinical experience in adults remains limited.

methodsPatient demographics, radiologic and pathologic characteristics, treatment course, progression, and patient survival were collected for 60 adult patients with DMG, H3 K27M-mutant. A subset of tumors also underwent next-generation sequencing. Analysis of progression-free survival and overall survival was conducted using Kaplan-Meier modeling, and univariate and multivariate analysis.

resultsMedian patient age was 32 years (range 18-71 years). Tumors were centered in the thalamus (

conclusionsTogether, these findings indicate that H3 K27M-mutant DMG represents a heterogeneous disease with regard to outcomes, sites of origin, and molecular pathogenesis in adults versus children.

Indexed as

adultdiffuse midline gliomageneticsH3 K27Msurvival

Identifiers

PMID33354667
PMCPMC7739048
OpenAlexW3094211562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.